Clinical trial
Nitrocamptothecin in Treating Patients With Advanced or Recurrent Colorectal…
NCT00005877 · Astex Pharmaceuticals, Inc., Industry · Unknown status
Key facts
| NCT number | NCT00005877 |
|---|---|
| Title | Nitrocamptothecin in Treating Patients With Advanced or Recurrent Colorectal Cancer |
| Official title | Phase II and Pharmacokinetic Study of RFS 2000 (9-Nitro-Camptothecin, 9-NC) in Patients With Advanced Colorectal Cancer Who Have Failed Previous 5-FU Based Chemotherapy |
| Lead sponsor | Astex Pharmaceuticals, Inc., Industry |
| Status | Unknown status |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Colorectal Cancer |
| Intervention type | Drug |
| Interventions | rubitecan |
| Start date | Sep 1, 1999 |
| First posted | Feb 12, 2004 |
| Last update posted | Dec 4, 2013 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: